PASW PASW
Company Profile ↓Company Overview
PASW (PASW) is a publicly traded company listed on with a market capitalization of $2.67M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.23.
Recent Developments
- Sep 2025 Revenue of $34.15M (-61.0% YoY); net profit $-12.83M.
- Trailing 12 Months Year-on-year growth — revenue -61.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -33.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -33.20% |
| 1 Year: | -61.03% |
Stock Price Performance
| 1 Year: | -92.63% |
| 6 Months: | -39.77% |
| 3 Months: | -19.94% |
| 1 Month: | -14.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -33.2% CAGR over 5 years.
- Trading 92.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Revenue | - | 114.55M | 82.56M | 87.62M | 34.15M |
| Cost of Revenue | - | 100.40M | 78.32M | 82.21M | 33.20M |
| Gross Profit | - | 14.14M | 4.24M | 5.42M | 949.50K |
| Operating Expenses | - | 2.99M | 3.63M | 5.42M | 15.65M |
| Operating Income | - | 11.15M | 612.48K | -2.04K | -14.70M |
| EBITDA | - | 11.61M | 1.81M | 473.34K | -14.37M |
| Interest Expense | - | 1.57M | 1.74M | 705.27K | 307.06K |
| Pretax Income | - | 9.63M | 41.69K | -682.72K | -14.68M |
| Tax Provision | - | 2.40M | 1.04M | 601.46K | -1.86M |
| Net Income | - | 7.23M | -993.94K | -1.28M | -12.83M |
| Diluted EPS | 0.38 | 0.35 | -0.05 | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 81.95M | 79.84M | 56.85M | 68.41M |
| Current Assets | - | 79.04M | 76.57M | 53.31M | 63.70M |
| Cash & Equivalents | - | 1.17M | 591.87K | 130.92K | 1.17M |
| Inventory | - | 4.63M | 3.19M | 127.30K | 441.90K |
| Receivables | - | 57.00M | 47.09M | 40.44M | 16.93M |
| Total Liabilities | - | 77.35M | 85.70M | 64.04M | 23.17M |
| Current Liabilities | - | 77.35M | 85.63M | 63.58M | 23.08M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 35.57M | 42.96M | 10.81M | 10.47M |
| Total Equity | - | 4.60M | -5.86M | -7.19M | 45.24M |
| Shares Outstanding | - | 20.50M | 20.50M | 20.50M | 20.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 21.09M | -6.08M | 14.63M | -6.43M |
| Investing Cash Flow | - | -30.26M | -3.37M | 15.00M | 0 |
| Financing Cash Flow | - | 10.24M | 8.87M | -30.09M | 43.66M |
| Capital Expenditure | -26.99K | -24.78K | - | - | - |
| Free Cash Flow | - | 21.06M | -6.08M | 14.63M | -6.43M |
| Net Change in Cash | - | 1.07M | -575.74K | -458.68K | 37.23M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 12.3% | 5.1% | 6.2% | 2.8% |
| Operating Margin % | - | 9.7% | 0.7% | -0.0% | -43.1% |
| Net Margin % | - | 6.3% | -1.2% | -1.5% | -37.6% |
| ROE % | - | 157.1% | 17.0% | 17.9% | -28.4% |
| ROCE % | - | 242.4% | -10.6% | 0.0% | -32.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PASW
Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years
HONG KONG, July 22, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (hereinafter referred to as “Ping An Biomedical”) announced that it has formally signed a strategic cooperation agreement with Yuan Sheng Mei Yan Healt…
All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital
HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that shareholders have approved all five resolutions at the company’s 2026 Annual General Meeting,…
Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry
HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotech…
Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation
HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors. Ping …
Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter
Hong Kong, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced receipt of Nasdaq Minimum Bid Price Deficiency Letter. On November 24, 2025, Ping An Biomedical Co., Ltd. (the “Company…
PASW — Frequently Asked Questions
What is the current share price of PASW?
As of 2026-08-05 17:25 PDT, PASW trades at $0.13 on NASDAQ/NYSE. Its 52-week range is $0.12 to $1.77.
What is the market capitalisation of PASW?
PASW has a market capitalisation of $2.67M on NASDAQ/NYSE.
What is the P/E ratio of PASW?
PASW trades at a trailing price-to-earnings (P/E) ratio of -2.68. Its price-to-book (P/B) ratio is 0.06.
What is the return on equity (ROE) of PASW?
PASW has a return on equity (ROE) of -28.36%. Its return on capital employed (ROCE) is -32.43%.
Is PASW a good stock to buy?
This page provides a data-driven analysis of PASW, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.